BioHarvest Sciences Announces Pricing of $17.4 Million Upsized Public Offering of Common Stock
Rhea-AI Summary
BioHarvest Sciences (NASDAQ: BHST) priced an underwritten public offering of 2,485,000 common shares at $7.00 per share, for gross proceeds of about $17.4 million, before underwriting discounts and expenses.
The company granted the underwriters a 30-day option to buy up to 372,750 additional shares at the public price less the underwriting discount. BioHarvest expects to close the offering on or about November 10, 2025, with Craig-Hallum as sole managing underwriter.
Net proceeds are expected to be used for R&D, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes. The offering is made under a Form F-3 shelf registration declared effective on September 8, 2025.
Positive
- Gross proceeds of $17.4 million to fund operations
- Proceeds earmarked for R&D, manufacturing, and CDMO expansion
- Includes plan for debt reduction or refinancing to strengthen balance sheet
Negative
- Issuance of 2,485,000 new shares will dilute existing shareholders
- Underwriters' 30-day option could add 372,750 shares, increasing dilution
News Market Reaction
On the day this news was published, BHST declined 8.94%, reflecting a notable negative market reaction. Argus tracked a trough of -11.0% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $14M from the company's valuation, bringing the market cap to $143M at that time. Trading volume was exceptionally heavy at 7.1x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 7, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the pricing of an underwritten public offering of 2,485,000 shares of common stock, no par value, and at a public offering price of
Craig-Hallum is acting as the sole managing underwriter for the offering.
BioHarvest expects to use the net proceeds of the offering for research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or debt refinancing, capital expenditures, and general corporate purposes, including funding working capital.
The offering is being made pursuant to a shelf registration statement on Form F-3 (File No. 333-289908), as amended, includng a base prospectus, relating to the shares of common stock to be issued in the proposed offering was initially filed with the Securities and Exchange Commission (the "SEC") on August 28, 2025 and was declared effective on September 8, 2025. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. BioHarvest has filed a preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering with the SEC. A final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying base prospectus relating to the securities being offered may be obtained, when available, from Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 323 North Washington Ave., Minneapolis, MN 55401, by telephone at (612) 334-6300 or by email at prospectus@chlm.com.
About BioHarvest
BioHarvest (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, of which provisions BioHarvest is availing itself. Such forward-looking statements include, but are not limited to, those regarding the anticipated completion of the offering, the anticipated gross proceeds from the offering and the anticipated use of proceeds from the offering. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as "believes," "expects," "may," "will," "could," "should," "seeks," "approximately," "intends," "plans," "estimates," or "anticipates," or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. BioHarvest assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise, except as required by law.
Please refer to BioHarvest's most recent Annual Report on Form 40-F and other subsequent filings with the SEC, which are available at the SEC's website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from BioHarvest's current expectations.
Contacts:
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHST@mzgroup.us
# # #
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273595
FAQ
How many shares is BioHarvest (BHST) offering and at what price?
What are the total expected gross proceeds from the BHST offering?
When does BioHarvest (BHST) expect to close the public offering?
Will the BHST offering allow underwriters to buy more shares?
How will BioHarvest (BHST) use the net proceeds from the offering?
Who is managing the BioHarvest (BHST) public offering?
